Abstract
Acute Kidney Injury (AKI) is a common syndrome in the clinic and has become a worldwide public health problem. Renal Ischemia-Reperfusion Injury (IRI) is the most common cause of AKI. So far, effective treatment is still lacking for renal IRI, resulting in a high mortality rate of AKI. Mesenchymal Stem Cells (MSCs), considered as a promising candidate for tissue repair and regenerative medicine have aroused an increasing concern in recent years for the capacity of self-renewal and multi-lineage differentiation. MSC-based therapy has drawn wide attention for its therapeutic potential in renal IRI. The administrated MSCs can alleviate the renal IRI and improve the renal function for its anti-inflammatory, immunomodulation properties. MSCs preferentially migrate into injured sites to play the role of tissue repair. Furthermore, MSCs can modify the microenvironment to promote the recovery of damaged renal tubular cells via paracrine factors. However, the poor kidney-directional homing and poor survival under ischemia environment have limited their beneficial effects. Genetic modification is an effective approach to increase the therapeutic action of MSCs. MSCs are modified with exogenous genes to enhance their innate properties. Here we review the current knowledge of gene-modified MSCs, their biological characteristics and applications in renal IRI.
Keywords: Mesenchymal stem cells, Genetic modification, Renal ischemia-reperfusion injury, Reactive oxygen species.
Current Gene Therapy
Title:Gene-modified Mesenchymal Stem Cell–based Therapy in Renal Ischemia- Reperfusion Injury
Volume: 17 Issue: 6
Author(s): Hongbo Xu, Cheng Chen, Linkun Hu*Jianquan Hou*
Affiliation:
- Department of Urology, The First Affiliated Hospital of Soochow University, 188 Shizi Rd, Suzhou 215006,China
- Department of Urology, The First Affiliated Hospital of Soochow University, 188 Shizi Rd, Suzhou 215006,China
Keywords: Mesenchymal stem cells, Genetic modification, Renal ischemia-reperfusion injury, Reactive oxygen species.
Abstract: Acute Kidney Injury (AKI) is a common syndrome in the clinic and has become a worldwide public health problem. Renal Ischemia-Reperfusion Injury (IRI) is the most common cause of AKI. So far, effective treatment is still lacking for renal IRI, resulting in a high mortality rate of AKI. Mesenchymal Stem Cells (MSCs), considered as a promising candidate for tissue repair and regenerative medicine have aroused an increasing concern in recent years for the capacity of self-renewal and multi-lineage differentiation. MSC-based therapy has drawn wide attention for its therapeutic potential in renal IRI. The administrated MSCs can alleviate the renal IRI and improve the renal function for its anti-inflammatory, immunomodulation properties. MSCs preferentially migrate into injured sites to play the role of tissue repair. Furthermore, MSCs can modify the microenvironment to promote the recovery of damaged renal tubular cells via paracrine factors. However, the poor kidney-directional homing and poor survival under ischemia environment have limited their beneficial effects. Genetic modification is an effective approach to increase the therapeutic action of MSCs. MSCs are modified with exogenous genes to enhance their innate properties. Here we review the current knowledge of gene-modified MSCs, their biological characteristics and applications in renal IRI.
Export Options
About this article
Cite this article as:
Xu Hongbo, Chen Cheng , Hu Linkun*, Hou Jianquan *, Gene-modified Mesenchymal Stem Cell–based Therapy in Renal Ischemia- Reperfusion Injury, Current Gene Therapy 2017; 17 (6) . https://dx.doi.org/10.2174/1566523218666180214094253
DOI https://dx.doi.org/10.2174/1566523218666180214094253 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biological Roles of the Eclectic Chromogranin-A-derived Peptide Catestatin
Current Medicinal Chemistry AMPK in Neurodegenerative Diseases: Implications and Therapeutic Perspectives
Current Drug Targets The Pathobiology of Endothelin-1 in Vein Graft Disease: Are ETA Receptor Antagonists the Solution to Prevent Vein Graft Failure?
Current Vascular Pharmacology Cyclophilin D as a Drug Target
Current Medicinal Chemistry Hepatocyte Growth Factor (HGF) for a Cell-Signal-Based Therapy During Acute and Chronic Liver Diseases
Current Signal Transduction Therapy Mitochondrion-Specific Antioxidants as Drug Treatments for Alzheimer Disease
CNS & Neurological Disorders - Drug Targets Role of Nitric Oxide in the Modulation of Angiogenesis
Current Pharmaceutical Design Cerebral White Matter Injuries Following a Hypoxic/Ischemic Insult During the Perinatal Period: Pathophysiology, Prognostic Factors, and Future Strategy of Treatment Approach. A Minireview
Current Pharmaceutical Design Tetramethylpyrazine Facilitates Functional Recovery after Spinal Cord Injury by Inhibiting MMP2, MMP9, and Vascular Endothelial Cell Apoptosis
Current Neurovascular Research Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine Optical Imaging of Microvascular Morphology and Perfusion
Current Angiogenesis (Discontinued) Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design Fetal Asphyctic Preconditioning Protects Against Perinatal Asphyxia- Induced Apoptosis and Astrogliosis in Neonatal Brain
CNS & Neurological Disorders - Drug Targets MicroRNAs in Noise-Induced Hearing Loss and their Regulation by Oxidative Stress and Inflammation
Current Drug Targets Pleiotropic Beneficial Effects of Epigallocatechin Gallate, Quercetin and Delphinidin on Cardiovascular Diseases Associated with Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Targeting Mitochondria: A New Promising Approach for the Treatment of Liver Diseases
Current Medicinal Chemistry Dynamics of Toll-like Receptors Signaling in Skeletal Muscle Atrophy
Current Medicinal Chemistry Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Melatonin, Autophagy and Intestinal Bowel Disease
Current Pharmaceutical Design